Esperion's CLEAR Outcomes trial shows NEXLETOL reduces CV risk 13-23% in statin-intolerant patients

Esperion Therapeutics, Inc.

NEXLETOL reduced MACE-4 by 13% (p=0.004), MACE-3 by 15% (p=0.006), heart attack by 23% (p=0.002), and coronary revascularization by 19% (p=0.001) vs placebo.
First LDL-C lowering therapy since statins to reduce hard ischemic events in both primary and secondary prevention patients.
Regulatory filings to FDA and EMA expected in 1H 2023; potential partner milestone payments up to $440M ($300M EU label, $140M other milestones).
Full-year 2023 operating expenses guided at $225M-$245M, including $25M non-cash stock compensation.
Results published in NEJM and presented at ACC.23/WCC; conference call scheduled for March 6, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.